We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
Read MoreHide Full Article
Illumina, Inc. (ILMN - Free Report) has been gaining investor confidence on consistently positive results. Over the past year, the company’s share price has outperformed its industry. The stock has gained 54.2% against the industry’s 8.5% fall. Also, the company has outperformed the S&P 500’s 13.2% gain.
This renowned sequencing and array-based genetic analysis solution provider has a market cap of $39.64 billion. The company has an earnings growth rate of 20% for the next three to five years.
With solid prospects, this Zacks Rank #1 (Strong Buy) stock is an attractive pick for investors at the moment.
The company’s estimate revision trend for the current year has been positive. In the past 60 days, 10 analysts revised their estimates upward with no movement in the opposite direction. Resultantly, earnings estimates rose around 5.4% to $4.84.
Let’s find out whether the recent positive trend is a sustainable one.
Solid Quarterly Performance
Illumina exited the first quarter of 2018 on a solid note with better-than-expected earnings and revenues. We are also encouraged by the significant year-over-year growth on both the counts. The substantial upside can be attributed to strong consumables growth across Illumina’s sequencing portfolio.
New Products Bode Well
We are upbeat about Illumina’s product launches which continue to contribute to the top line. Management is hopeful about the recently-launched NovaSeq S1 flow cell reagent kit. The company also received product approval certificate for the NextSeq 550Dx instrument from the Ministry of Food and Drug Safety (MFDS) in South Korea.
Last November, Illumina introduced NextSeq 550Dx instrument as well. This is the company’s second FDA-regulated and CE-IVD marked next-generation sequencing (NGS) system.
Efforts to Grow in Oncology Space
llumina’s collaborations with Bristol-Myers Squibb and Loxo Oncology in the field of clinical oncology applications are expected to garner positive results. The alliance with Bristol-Myers Squibb will utilize Illumina’s NGS technology to develop and globally commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb’s oncology portfolio.
We also look forward to GRAIL, Illumina’s recently-developed company focused on the cancer screening market. We believe GRAIL is expected to significantly expand Illumina’s share in the multi-billion dollar oncology market.
Geographic Expansion
Apart from North America, Illumina markets and distributes products directly to customers in Europe, Latin America, and the Asia-Pacific (APAC) region either through its direct selling force or through distributors that specialize in life science products.
In the first quarter, Illumina witnessed 21% growth in the APAC region propelled by 38% shipment growth in Greater China. Obviously, among the emerging markets, China is currently the most favorable space for Illumina’s business.
In recent times, management has noticed a considerable increase in demand as customers attempt to set up NIPT operations in China. We believe this recent progress in China will open up avenues for Illumina, thereby enhancing business growth.
Intuitive Surgical has a long-term expected earnings growth rate of 12.1%.
Chemed has a long-term expected earnings growth rate of 10%.
Amedisys has a long-term expected earnings growth rate of 17.5%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Here's Why You Should Invest in Illumina (ILMN) Stock Now
Illumina, Inc. (ILMN - Free Report) has been gaining investor confidence on consistently positive results. Over the past year, the company’s share price has outperformed its industry. The stock has gained 54.2% against the industry’s 8.5% fall. Also, the company has outperformed the S&P 500’s 13.2% gain.
This renowned sequencing and array-based genetic analysis solution provider has a market cap of $39.64 billion. The company has an earnings growth rate of 20% for the next three to five years.
With solid prospects, this Zacks Rank #1 (Strong Buy) stock is an attractive pick for investors at the moment.
The company’s estimate revision trend for the current year has been positive. In the past 60 days, 10 analysts revised their estimates upward with no movement in the opposite direction. Resultantly, earnings estimates rose around 5.4% to $4.84.
Let’s find out whether the recent positive trend is a sustainable one.
Solid Quarterly Performance
Illumina exited the first quarter of 2018 on a solid note with better-than-expected earnings and revenues. We are also encouraged by the significant year-over-year growth on both the counts. The substantial upside can be attributed to strong consumables growth across Illumina’s sequencing portfolio.
New Products Bode Well
We are upbeat about Illumina’s product launches which continue to contribute to the top line. Management is hopeful about the recently-launched NovaSeq S1 flow cell reagent kit. The company also received product approval certificate for the NextSeq 550Dx instrument from the Ministry of Food and Drug Safety (MFDS) in South Korea.
Last November, Illumina introduced NextSeq 550Dx instrument as well. This is the company’s second FDA-regulated and CE-IVD marked next-generation sequencing (NGS) system.
Efforts to Grow in Oncology Space
llumina’s collaborations with Bristol-Myers Squibb and Loxo Oncology in the field of clinical oncology applications are expected to garner positive results. The alliance with Bristol-Myers Squibb will utilize Illumina’s NGS technology to develop and globally commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb’s oncology portfolio.
We also look forward to GRAIL, Illumina’s recently-developed company focused on the cancer screening market. We believe GRAIL is expected to significantly expand Illumina’s share in the multi-billion dollar oncology market.
Geographic Expansion
Apart from North America, Illumina markets and distributes products directly to customers in Europe, Latin America, and the Asia-Pacific (APAC) region either through its direct selling force or through distributors that specialize in life science products.
In the first quarter, Illumina witnessed 21% growth in the APAC region propelled by 38% shipment growth in Greater China. Obviously, among the emerging markets, China is currently the most favorable space for Illumina’s business.
In recent times, management has noticed a considerable increase in demand as customers attempt to set up NIPT operations in China. We believe this recent progress in China will open up avenues for Illumina, thereby enhancing business growth.
Other Key Picks
Other top-ranked stocks in the broader medical sector are Intuitive Surgical (ISRG - Free Report) , Chemed Corporation (CHE - Free Report) and Amedisys, Inc. (AMED - Free Report) . While Intuitive Surgical and Chemed sport a Zacks Rank #1, Amedisys carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical has a long-term expected earnings growth rate of 12.1%.
Chemed has a long-term expected earnings growth rate of 10%.
Amedisys has a long-term expected earnings growth rate of 17.5%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>